ex_736281.htm

EX-99.2 5 ex_736281.htm EXHIBIT 99.2 ex_736281.htm

譲渡異議申立書 99.2

この文書は、1933年の証券法に登録された証券をカバーする目論見書の10(a)セクションの一部を構成しています.

Moleculin Biotech、Inc. 2024株式プラン

インセンティブ株式オプション契約

以下に識別された従業員は、Moleculin Biotech, Inc. 2024株式プラン（以下、「2024プラン」）の参加者として選ばれ、以下に概説されたインセンティブ株オプションが付与されました:

参加者:

付与日：

オプションでカバーされる株式数:

オプション行使価格： $

有効期限日：

Vesting Schedule: オプションは、付与日（すなわち付与日の翌年記念日に最初の分割が付与されます）の翌々年記念日まで、均等割りで各分割を取得し（または各分割で__________株ずつ）、参加者が当該取得日に会社にサービスを提供していることが条件となります。

上記の授与日から有効となるこの契約は、デラウェア州法人であるMoleculin Biotech, Inc.（以下、「当社」という）と上記の参加者との間で締結されます。当事者は以下の通り合意します:

2024年計画は、オプションを規制する条件の完全な説明を提供します。この規約と2024年計画との間に不一致がある場合は、2024年計画の条件が優先されます。全ての大文字で表記された用語は、これに別段記載されていない限り、2024年計画で定義される意味を持ちます。2024年計画のコピーが添付されており、2024年計画の条件は参照によってここに取り込まれます。

1. ストックオプション付与本契約の規定および2024年計画の条件に従い、かつ当事者の同意を考慮して、会社はここに、参加者が会社から普通株式の株式を購入するオプションを与えます。株式単価を、および上記に設定されたスケジュール通りに。この付与は、1986年改訂版(以下『法典』)の第422(b)条に記載されているようなインセンティブストックオプションであることを意図しています。

2. 参加者の承認このオプションの行使は、参加者によるこの契約の承認にかかっています。

3. オプションの行使以下のセクション4に従う限り、参加者は満期日までいつでもオプションの一部を行使することができます。オプションの一部を行使する選択は、参加者または参加者がチーフファイナンシャルオフィサーである場合はチーフエグゼクティブオフィサーに、任意の事前通知を、参加者の死亡の場合はその代表者が、その行使時に有効な「会社の取締役会（「委員会」という）の報酬委員会が決定した手続きに従って会社に提供しなければならない。」

オプションの行使時には、オプションの行使により普通株式の株式購入価格の支払いは、次のいずれかの方法によって行われなければなりません：（a）現金で、（b）参加者が行使の通知と普通株式の購入価格を会社に売却対象の株式の売却代金から支払うように指示し不可撤品のブローカーディーラーから現金を受け取る、（c）行使の通知に基づき、普通株式の発行があった場合には、株式の数量に等しい額の購入価格、および/または購入価格に等しい数量の現在の公正市場価値を一致させるように会社に引き渡す、および/または（d）会社にその他の普通株式を提供し、その時点での公正市場価値で評価される参加者の妥当とされる普通株式。

オプションの行使による株式の発行は、行使価格の全額支払いが完了するまで行われません。

オプションの一部にかかる株式の公正市場価値（各オプションの付与時に決定される）がカレンダー年につき100,000ドルを超える場合、この制限を超えるそのオプションの部分は非資格付ストックオプションとなります。したがって、オプションの付与または加速された付与によって、オプションのすべてまたは一部が非資格付ストックオプションとして取り扱われることがあります。

4. 雇用終了時の行使参加者の雇用者が自己の裁量により決定する事由以外の死亡、障害又は老後生活以外の理由により、会社および全セクターとの雇用が終了した場合、その時点でのオプションの実施権の一部は、参加者の終了日から90日後またはオプションの規定によりオプションが満期となる日のいずれか早い日まで行使可能となります。雇用終了時点でのオプションの未実施部分はその日付で消滅し、行使できません。

もし参加者の雇用が死亡、障害、あるいは老後生活によって会社および全セクターで終了した場合、その時点で株式オプションの帰属部分は、参加者の終了日から1年後、もしくはオプションが規定により満了する日のいずれか早い日まで行使可能であり続けます。終了日時点で未帰属となっているオプションの部分は、その終了日をもって失効し、行使できません。

参加者の会社及び全セクターとの雇用が会社によって理由(委員会の独自の裁量により決定)で終了された場合、そのオプションはその終了日に期限切れとなり、その終了日以降に行使可能な部分はありません。

本セクション 4 の目的のために、(A) 「障害」とは、参加者が参加する会社の長期障害プログラムで設定され、および決定される意味であり、(B)「退職」とは、参加者が65歳以上であるか、又は55歳以上で会社及びその子会社との10年の勤務経験を有している場合に、会社及びその子会社との雇用を解除されたことを意味します（委員会が独自の裁量で決定する「正当な理由なし」）。

本条項4の前述の規定は、参加者と会社との間で締結された又は締結される可能性のある任意の従業契約又は解雇契約の規定に準じます。オプションの行使に関する前述の従業契約又は解雇契約の規定は、本条項4の矛盾する規定又は反対する規定を取って代わります。

5. 守秘義務と競業避止契約。本契約の他の規定にかかわらず、参加者が参加者と会社の間で有効な秘密保持契約および/または競業避止契約の条項に違反したと委員会が判断した場合、（a）オプションの未払いで行使されなかった部分（権利確定か否かを問わず）は取り消され、会社に没収され、（b）参加者は書面による通知から30日以内に会社に送金するものとします。委員会から、対象となる普通株式の数に等しい現金支払い以前に行使されたオプションの一部に、オプション行使価格に対する行使日の普通株式の公正市場価値の超過分を掛けたもの。当社は、適用法で認められるとおり、当社が参加者に支払うべき金額から当該支払額を差し引く権利を有します。

6. Nontransferability of Options. The Option may not be sold, transferred, pledged, assigned, or otherwise alienated or hypothecated, other than by will or by the laws of descent and distribution.

7. Beneficiary Designation. The Participant may, from time to time, name any beneficiary or beneficiaries (who may be named contingently or successively) to whom any benefit under the Option is to be paid in the event of his or her death. Each designation will revoke all prior designations by the same Participant, shall be in a form prescribed by the Board, and will be effective only when filed by the Participant in writing with the Board during his or her lifetime. In the absence of any such designation, or if all beneficiaries predecease the Participant, benefits remaining unpaid at the Participant’s death shall be paid to the Participant’s estate.

8. Rights as a Stockholder. The Participant shall have no rights as a stockholder of the Company with respect to the shares of Common Stock subject to the Option and this Agreement until such time as the exercise price has been paid and the shares have been issued and delivered to him or her.

9. Surrender of or Changes to Agreement. In the event the Option shall be exercised in whole, this Agreement shall be surrendered to the Company for cancellation. In the event the Option shall be exercised in part or a change in the number of designation of the shares of Common Stock shall be made, this Agreement shall be delivered by the Participant to the Company for the purpose of making appropriate notation thereon, or of otherwise reflecting, in such manner as the Company shall determine, the change in the number or designation of such shares.

10. Administration. The Option shall be exercised in accordance with such administrative regulations as the Committee shall from time to time adopt. It is expressly understood that the Committee is authorized to administer, construe, and make all determinations necessary or appropriate to the administration of, the 2024 Plan and this Agreement, all of which shall be binding upon the Participant.

11. Governing Law. This Agreement, and the Option, shall be construed, administered and governed in all respects under and by the laws of the State of Delaware.

* * *

By accepting this Agreement, the Participant agrees to be bound by the terms hereof.

	Moleculin Biotech, Inc.

	By:

	Title:
	Participant

By:

Print Name:

THIS DOCUMENT CONSTITUTES PART OF THE SECTION 10(a) PROSPECTUS COVERING SECURITIES THAT HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933.

Moleculin Biotech, Inc. 2024 Stock Plan

Non-Qualified Stock Option Agreement (for individuals other than independent directors)

The employee identified below has been selected to be a Participant in the Moleculin Biotech, Inc. 2024 Stock Plan (the “2024 Plan”) and has been granted a Non-Qualified Option as outlined below:

Participant:

Date of Grant:

Shares Covered by the Option:

Option Exercise Price: $

Expiration Date:

Vesting Schedule: The Option shall vest in __________equal installments (or ________shares each installment) on each of the succeeding __________ anniversary dates of the Date of Grant (i.e. the first such installment shall vest on the first anniversary of the Date of Grant), provided Participant is providing services to the Company on such vesting date(s).

This Agreement, effective as of the Date of Grant set forth above, is between Moleculin Biotech, Inc., a Delaware corporation (the “Company”), and the Participant named above. The parties hereto agree as follows:

The 2024 Plan provides a complete description of the terms and conditions governing the Option. If there is any inconsistency between the terms of this Agreement and the terms of the 2024 Plan, the 2024 Plan’s terms shall govern. All capitalized terms shall have the meanings ascribed to them in the 2024 Plan, unless otherwise set forth herein. A copy of the 2024 Plan is attached hereto and the terms of the 2024 Plan are hereby incorporated by reference.

1. Stock Option Grant. Subject to the provisions set forth herein and the terms and conditions of the 2024 Plan, and in consideration of the agreements of the Participant herein provided, the Company hereby grants to the Participant an Option to purchase from the Company the number of shares of Common Stock, at the exercise price per share, and on the schedule, set forth above.

2. Acceptance by Participant. The exercise of the Option is conditioned upon the acceptance of this Agreement by the Participant.

3. Exercise of Option. Subject to Section 4 below, the Participant may exercise the vested portion of the Option at any time prior to the Expiration Date. Written notice of an election to exercise any portion of the Option shall be given by the Participant, or his personal representative in the event of the Participant’s death, to the Company’s Chief Financial Officer (or Chief Executive Officer if the Participant is the Chief Financial Officer), in accordance with procedures established by the Compensation Committee of the Board of Directors of the Company (the “Committee”) as in effect at the time of such exercise.

At the time of exercise of the Option, payment of the purchase price for the shares of Common Stock with respect to which the Option is exercised, and of an amount sufficient to satisfy all minimum Federal, state and local withholding tax requirements, must be made by one or more of the following methods: (a) in cash, (b) in cash received from a broker-dealer to whom the Participant has submitted an exercise notice and irrevocable instructions to deliver the purchase price or withholding tax to the Company from the proceeds of the sale of shares subject to the Option, (c) by directing the Company to withhold such number of shares of Common Stock otherwise issuable upon exercise of the Option with a fair market value equal to the amount of the purchase price or the tax to be withheld and/or (d) by delivery to the Company of other Common Stock owned by the Participant that is acceptable to the Company, valued at its then fair market value.

No shares shall be issued upon exercise of the Option until full payment of the exercise price and tax withholding obligation has been made.

4. Exercise Upon Termination of Employment. If the Participant’s employment with the Company and all subsidiaries terminates without cause (as determined by the Committee in its sole discretion) and for any reason other than death, disability or retirement, the then vested portion of the Option shall continue to be exercisable until the earlier of the 90th day after the date of the Participant’s termination or the date the Option expires by its terms. The portion of the Option not vested as of the date of such termination of employment shall expire as of such date and shall not be exercisable.

If the Participant’s employment with the Company and all subsidiaries terminates due to death, disability or retirement, the then vested portion of the Option shall continue to be exercisable until the earlier of one year after the date of the Participant’s termination or the date the Option expires by its terms. The portion of the Option not vested as of the date of such termination of employment shall expire as of such date and shall not be exercisable.

If the Participant’s employment with the Company and all subsidiaries is terminated by the Company for cause (as determined by the Committee in its sole discretion), the Option shall expire on the date of such termination, and no portion shall be exercisable after the date of such termination.

For purposes of this Section 4, (A) “disability” has the meaning, and will be determined, as set forth in the Company’s long term disability program in which the Participant participates, and (B) “retirement” means the Participant’s termination from employment with the Company and all subsidiaries without cause (as determined by the Committee in its sole discretion) when the Participant is 65 or older or 55 or older with 10 years of service with the Company and its subsidiaries.

The foregoing provisions of this Section 4 shall be subject to the provisions of any written employment or severance agreement that has been or may be executed by the Participant and the Company, and the provisions in such employment or severance agreement concerning exercise of the Option shall supersede any inconsistent or contrary provision of this Section 4.

5. Confidentiality and Non-Compete Agreement. Notwithstanding any other provision of this Agreement, in the event the Committee determines that the Participant has breached any provision of any confidentiality and/or non-compete agreement in effect between the Participant and the Company, (a) the then outstanding and unexercised portion of the Option (whether vested or unvested) shall be cancelled and forfeited back to the Company and (b) the Participant shall remit to the Company within 30 days of written notice from the Committee a cash payment equal to the number of shares of Common Stock subject to the portion of the Option that was previously exercised, multiplied by the excess of the fair market value of the Common Stock on the date of exercise over the Option Exercise Price. The Company shall be entitled, as permitted by applicable law, to deduct the amount of such payment from any amounts the Company may owe to the Participant.

11. Governing Law. This Agreement, and the Option, shall be construed, administered and governed in all respects under and by the laws of the State of Delaware.

* * *

By accepting this Agreement, the Participant agrees to be bound by the terms hereof.

	Moleculin Biotech, Inc.


	By:

	Title:

	Participant

By:

Print Name:

THIS DOCUMENT CONSTITUTES PART OF THE SECTION 10(a) PROSPECTUS COVERING SECURITIES THAT HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933.

Moleculin Biotech, Inc. 2024 Stock Plan

Non-Qualified Stock Option Agreement (for non-employee Directors)

The director identified below has been selected to be a Participant in the Moleculin Biotech, Inc. 2024 Stock Plan (the “2024 Plan”) and has been granted a Non-Qualified Option as outlined below:

Participant:

Date of Grant:

Shares Covered by the Option:

Option Exercise Price: $

Expiration Date:

Vesting Schedule: The Option shall vest in four (4) equal quarterly installments (or ______ shares per installment) on each of the succeeding four quarters after the Date of Grant, provided Participant is serving as a member of the Company’s Board of Directors on such vesting dates.

12. Stock Option Grant. Subject to the provisions set forth herein and the terms and conditions of the 2024 Plan, and in consideration of the agreements of the Participant herein provided, the Company hereby grants to the Participant an Option to purchase from the Company the number of shares of Common Stock, at the exercise price per share, and on the schedule, set forth above.

13. Acceptance by Participant. The exercise of the Option is conditioned upon the acceptance of this Agreement by the Participant.

14. Exercise of Option. Subject to Section 4 below, the Participant may exercise the vested portion of the Option at any time prior to the Expiration Date. Written notice of an election to exercise any portion of the Option shall be given by the Participant, or his personal representative in the event of the Participant’s death, to the Company’s Chief Financial Officer (or Chief Executive Officer if the Participant is the Chief Financial Officer), in accordance with procedures established by the Compensation Committee of the Board of Directors of the Company (the “Committee”) as in effect at the time of such exercise.

No shares shall be issued upon exercise of the Option until full payment of the exercise price and tax withholding obligation has been made.

15. Exercise Upon Termination of Service. If the Participant’s service as a member of the Company’s Board of Directors terminates for any reason other than death, disability or retirement, the then vested portion of the Option shall continue to be exercisable until the earlier of the 90th day after the date of the Participant’s termination or the date the Option expires by its terms. The portion of the Option not vested as of the date of such termination of service shall expire as of such date and shall not be exercisable.

If the Participant’s service as a member of the Company’s Board of Directors terminates due to death, disability or retirement, the then vested portion of the Option shall continue to be exercisable until the earlier of one year after the date of the Participant’s termination or the date the Option expires by its terms. The portion of the Option not vested as of the date of such termination of service shall expire as of such date and shall not be exercisable.

For purposes of this Section 4, (A) “disability” has the meaning, and will be determined, as set forth in the Company’s long term disability program in which the Participant participates, and (B) “retirement” means the Participant’s termination from service as a member of the Company’s Board of Directors when the Participant is 65 or older or 55 or older with 10 years of service with the Company and its subsidiaries.

16. Confidentiality and Non-Compete Agreement. Notwithstanding any other provision of this Agreement, in the event the Committee determines that the Participant has breached any provision of any confidentiality and/or non-compete agreement in effect between the Participant and the Company, (a) the then outstanding and unexercised portion of the Option (whether vested or unvested) shall be cancelled and forfeited back to the Company and (b) the Participant shall remit to the Company within 30 days of written notice from the Committee a cash payment equal to the number of shares of Common Stock subject to the portion of the Option that was previously exercised, multiplied by the excess of the fair market value of the Common Stock on the date of exercise over the Option Exercise Price. The Company shall be entitled, as permitted by applicable law, to deduct the amount of such payment from any amounts the Company may owe to the Participant.

17. Nontransferability of Options. The Option may not be sold, transferred, pledged, assigned, or otherwise alienated or hypothecated, other than by will or by the laws of descent and distribution.

18. Beneficiary Designation. The Participant may, from time to time, name any beneficiary or beneficiaries (who may be named contingently or successively) to whom any benefit under the Option is to be paid in the event of his or her death. Each designation will revoke all prior designations by the same Participant, shall be in a form prescribed by the Board, and will be effective only when filed by the Participant in writing with the Board during his or her lifetime. In the absence of any such designation, or if all beneficiaries predecease the Participant, benefits remaining unpaid at the Participant’s death shall be paid to the Participant’s estate.

19. Rights as a Stockholder. The Participant shall have no rights as a stockholder of the Company with respect to the shares of Common Stock subject to the Option and this Agreement until such time as the exercise price has been paid and the shares have been issued and delivered to him or her.

20. Surrender of or Changes to Agreement. In the event the Option shall be exercised in whole, this Agreement shall be surrendered to the Company for cancellation. In the event the Option shall be exercised in part or a change in the number of designation of the shares of Common Stock shall be made, this Agreement shall be delivered by the Participant to the Company for the purpose of making appropriate notation thereon, or of otherwise reflecting, in such manner as the Company shall determine, the change in the number or designation of such shares.

21. Administration. The Option shall be exercised in accordance with such administrative regulations as the Committee shall from time to time adopt. It is expressly understood that the Committee is authorized to administer, construe, and make all determinations necessary or appropriate to the administration of, the 2024 Plan and this Agreement, all of which shall be binding upon the Participant.

22. Governing Law. This Agreement, and the Option, shall be construed, administered and governed in all respects under and by the laws of the State of Delaware.

* * *

By accepting this Agreement, the Participant agrees to be bound by the terms hereof.

	Moleculin Biotech, Inc.


	By:

	Title:

	Participant

By:

Print Name:

THIS DOCUMENT CONSTITUTES PART OF THE SECTION 10(a) PROSPECTUS COVERING SECURITIES THAT HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933.

Moleculin Biotech, Inc. 2024 Stock Plan

Restricted Stock Unit Award Agreement (for Key Employees)

A Restricted Stock Unit (“RSU”) Award (the “Award”) is hereby granted by Moleculin Biotech, Inc., a Delaware corporation (the “Company”), to the Key Employee named below (the “Grantee”), relating to the Common Stock of the Company:

Key Employee         :
Date of Award:
Number of RSUs Subject to Award:
End of Vesting Period:

The Award shall be subject to the following terms and conditions and the provisions of the Moleculin Biotech, Inc. 2024 Stock Plan (the “2024 Plan”), a copy of which is attached hereto and the terms of which are hereby incorporated by reference:

1. Grant of Award. The Company hereby grants to the Grantee the Award of RSUs. An RSU is the right, subject to the terms and conditions of the 2024 Plan and this Agreement, to receive a distribution of one share of Common Stock.

2. Acceptance by Grantee. The receipt of the Award is conditioned upon its acceptance by the Grantee in the space provided therefor at the end of this Agreement and the return of an executed copy of this Agreement to the Secretary of the Company. If the Grantee shall fail to return this executed Agreement, the Grantee’s Award shall be forfeited to the Company.

3. RSU Account. The Company shall maintain an account (the “RSU Account”) on its books in the name of the Grantee which shall reflect the number of RSUs awarded to the Grantee and any dividend equivalents paid to the Grantee as described in Section 4.

4. Dividend Equivalents. Upon the payment of any dividends on Common Stock occurring during the period beginning on the date of the Award and ending on the date the RSUs are settled in Common Stock (or the date the RSUs are forfeited), the Company shall credit the Grantee’s RSU Account with an amount equal in value to the dividends that the Grantee would have received had the Grantee been the actual owner of the number of shares of Common Stock represented by the RSUs in the Grantee’s RSU Account on that date. Such amounts shall be paid to the Grantee in cash at the time and to the extent the RSU Account is distributed to the Grantee. Any dividend equivalents relating to RSUs that are forfeited shall also be forfeited.

5. Nontransferability. Except as set forth in Section 12 of the 2024 Plan, neither the Award nor any of the RSUs subject to the Award may be sold, assigned, pledged, encumbered or otherwise transferred, voluntarily or involuntarily. Any attempted sale, assignment, pledge, encumbrance or transfer of the Award, other than in accordance with its terms, shall be void and of no effect.

6. Vesting.

(a) Except as set forth in (b) and (c) below, the Grantee shall become vested in the Award as follows: _________________________

(b) If the Grantee’s employment with the Company and all Subsidiaries terminates for any reason, unvested RSUs subject to the Award shall be forfeited to the Company, and the Grantee’s rights, title and interest with respect to such forfeited RSUs shall automatically lapse and be of no further force or effect. The Grantee hereby irrevocably designates and appoints the Secretary of the Company as the Grantee’s agent and attorney in fact, to act for or on behalf of the Grantee and in his name and stead, for the limited purpose of executing any documents and instruments to further evidence the forfeiture of the unvested RSUs.

(c) The foregoing provisions of this Section 6 shall be subject to the provisions of any written employment or severance agreement that has been or may be executed by the Grantee and the Company, and the provisions in such employment or severance agreement concerning the vesting of an Award shall supersede any inconsistent or contrary provision of this Section 6.

7. Settlement of Award. If the Grantee becomes vested in the Award in accordance with Section 6, within 30 days following the date of vesting, the Company shall distribute to the Grantee, or his or her personal representative, beneficiary or estate, as applicable, (a) a number of shares of Common Stock equal to the number of vested RSUs subject to the Award and (b) a cash payment equal to the dividend equivalents that are payable pursuant to Section 4.

8. Withholding Taxes. The Grantee shall pay to the Company an amount sufficient to satisfy all minimum Federal, state and local withholding tax requirements prior to the delivery of any shares of Common Stock upon settlement of any vested RSUs covered by the Award. The Company in its sole discretion may permit the payment of additional withholding taxes up to the maximum statutory rate. Payment of such taxes may be made by one or more of the following methods: (a) in cash, (b) in cash received from a broker-dealer to whom the Grantee has submitted a notice and irrevocable instructions to deliver to the Company proceeds from the sale of a portion of the shares deliverable upon settlement of the Award, (c) by delivery to the Company of other Common Stock owned by the Grantee that is acceptable to the Company, valued at its then Fair Market Value, and/or (d) by directing the Company to withhold such number of shares of Common Stock otherwise deliverable upon settlement of the Award with a Fair Market Value equal to the amount of tax to be withheld.

9. Share Delivery. Delivery of shares of Common Stock upon settlement of the Award will be by book-entry credit to an account in the Grantee’s name established by the Company with the Company’s transfer agent; provided that the Company shall, upon written request from the Grantee (or his estate or personal representative, as the case may be), issue certificates in the name of the Grantee (or his estate or personal representative) representing such Award shares.

10. Rights as Stockholder. The Grantee shall not be entitled to any of the rights of a stockholder of the Company with respect to the Award, including the right to vote and to receive dividends and other distributions, until and to the extent the Award is settled in shares of Common Stock.

11. Insider Trading Policy. The sale or transfer of any shares of Common Stock delivered upon settlement of the Award is subject to the provisions of the Company’s Insider Trading Policy, as in effect from time to time.

12. Recoupment. Notwithstanding any other provision of this Agreement, to the extent required by applicable law, including the Dodd-Frank Wall Street Reform and Consumer Protection Act, the Company shall have the right to seek recoupment of all or any portion of an Award (including by forfeiture of any outstanding Award or by the Grantee’s remittance to the Company of vested Award shares or of a cash payment equal to the vested Award shares). The value with respect to which such recoupment is sought shall be determined by the Committee. The Committee shall be entitled, as permitted by applicable law, to deduct the amount of such payment from any amounts the Company may owe to the Grantee.

13. Employment Status. This Agreement does not give the Grantee the right to be retained as an employee of the Company.

14. Administration. The Award shall be administered in accordance with such regulations as the Committee shall from time to time adopt.

15. Plan Governs. If there is any inconsistency between the terms of this Agreement and the terms of the 2024 Plan, the 2024 Plan’s terms shall govern. All capitalized terms shall have the meanings ascribed to them in the 2024 Plan, unless specifically set forth otherwise herein.

16. Governing Law. This Agreement, and the Award, shall be construed, administered and governed in all respects under and by the laws of the State of Delaware.

IN WITNESS WHEREOF, this Agreement is executed effective as of the ____ day of _____, 20___.

	MOLECULIN BIOTECH, INC.



	By:

AGREED AND ACCEPTED:

I acknowledge receipt of the Moleculin Biotech, Inc. 2024 Stock Plan, and hereby accept this Restricted Stock Unit Award subject to all the terms and conditions thereof. I agree to accept as binding, conclusive and final all decisions and interpretations of the Committee regarding any questions arising under the 2024 Plan or this Award Agreement.

GRANTEE

Print Name:


Signature:


Date: